EPIZYME, INC. (NASDAQ:EPZM) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August4, 2017, Epizyme, Inc., a Delaware corporation (the “Company”) announced its financial results for the quarter ended June30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information provided under Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02 | Financial Statements and Exhibits |
| 99.1 | Press release issued by the Company on August4, 2017* |
| * | The exhibit shall be deemed to be furnished, and not filed. |
Epizyme, Inc. ExhibitEX-99.1 2 d427166dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress Key Clinical Milestones Achieved in Studies of Mesothelioma,…To view the full exhibit click here
About EPIZYME, INC. (NASDAQ:EPZM)
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.